Key Points
- Insider buying: Hikma Pharmaceuticals insider Tobias Hestler purchased 7,500 shares at GBX 1,648 each, totaling approximately £123,600.
- Stock performance: Shares opened at GBX 1,638, compared with a 52-week range of GBX 1,187 to GBX 1,865; the company has a £3.42 billion market capitalization and a P/E ratio of 9.05.
- Analyst outlook: Six analysts rate Hikma a Buy, with a consensus price target of GBX 2,098. Recent firms including Deutsche Bank, Berenberg, Jefferies, and Citigroup maintained or assigned Buy ratings.
Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was bought at an average cost of GBX 1,648 per share, for a total transaction of £123,600.
Hikma Pharmaceuticals Stock Performance
Shares of Hikma Pharmaceuticals stock opened at GBX 1,638 on Wednesday. Hikma Pharmaceuticals PLC has a one year low of GBX 1,187 and a one year high of GBX 1,865. The company has a market cap of £3.42 billion, a PE ratio of 9.05, a P/E/G ratio of 2.38 and a beta of 0.66. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. The business has a 50-day simple moving average of GBX 1,542.79 and a 200-day simple moving average of GBX 1,454.39.
Wall Street Analysts Forecast Growth
Several research firms have commented on HIK. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Berenberg Bank raised their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a "buy" rating in a report on Tuesday. Jefferies Financial Group lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a "buy" rating in a research report on Tuesday, May 5th. Finally, Citigroup reiterated a "buy" rating on shares of Hikma Pharmaceuticals in a research note on Thursday, July 16th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of GBX 2,098.
Get Our Latest Stock Analysis on HIK
About Hikma Pharmaceuticals
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
